Biofilms: A developmental niche for vancomycin-intermediate Staphylococcus aureus

被引:0
|
作者
Chapman, Jenelle E. [1 ]
George, Shilpa E. [2 ]
Wolz, Christiane [2 ]
Olson, Michael E. [1 ,3 ]
机构
[1] Southern Illinois Univ, Dept Med Microbiol Immunol & Cell Biol, Sch Med, Springfield, IL USA
[2] Univ Tubingen, Interfac Inst Microbiol & Infect Med, Tubingen, Germany
[3] 800 N Rutledge St, Springfield, IL 62702 USA
关键词
Staphylococcus aureus; Biofilm; Insurance hypothesis; DNA repair; Vancomycin; COMPLETE GENOME SEQUENCE; SOS RESPONSE; ANTIBIOTIC-RESISTANCE; 2-COMPONENT SYSTEM; GENE; MECHANISMS; PROTEIN; STRAIN; EPIDEMIOLOGY; INFECTIONS;
D O I
10.1016/j.meegid.2023.105545
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Staphylococcus aureus are gram-positive bacteria responsible for a wide array of diseases, ranging from skin and soft tissue infections to more chronic illnesses such as toxic shock syndrome, osteomyelitis, and endocarditis. Vancomycin is currently one of the most effective antibiotics available in treating patients infected with methicillin-resistant S. aureus (MRSA), however the emergence of vancomycin-resistant S. aureus (VRSA), and more commonly vancomycin-intermediate S. aureus (VISA), threaten the future efficacy of vancomycin. Intermediate resistance to vancomycin occurs due to mutations within the loci of Staphylococcal genes involved in cell wall formation such as rpoB, graS, and yycG. We hypothesized the VISA phenotype may also arise as a result of the natural stress occurring within S. aureus biofilms, and that this phenomenon is mediated by the RecA/SOS response. Wildtype and recA null mutant/lexAG94E strains of S. aureus biofilms were established in biofilm microtiter assays or planktonic cultures with or without the addition of sub-inhibitory concentrations of vancomycin (0.063 mg/l - 0.25 mg/L ciprofloxacin, 0.5 mg/l vancomycin). Efficiency of plating techniques were used to quantify the subpopulation of biofilm-derived S. aureus cells that developed vancomycin-intermediate resistance. The results indicated that a greater subpopulation of cells from wildtype biofilms (4.16 x 102 CFUs) emerged from intermediate-resistant concentrations of vancomycin (4 mu g/ml) compared with the planktonic counterpart (1.53 x 101 CFUs). Wildtype biofilms (4.16 x 102 CFUs) also exhibited greater resistance to intermediate-resistant concentrations of vancomycin compared with strains deficient in the recA null mutant (8.15 x 101 CFUs) and lexA genes (8.00 x 101 CFUs). While the VISA phenotype would be an unintended consequence of genetic diversity and potentially gene transfer in the biofilm setting, it demonstrates that mutations occurring within biofilms allow for S. aureus to adapt to new environments, including the presence of widely used antibiotics.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Characterization of Infections with Vancomycin-Intermediate Staphylococcus aureus (VISA) and Staphylococcus aureus with Reduced Vancomycin Susceptibility in South Korea
    Jung Wan Park
    Hyungmin Lee
    Jung Wook Kim
    Bongyoung Kim
    Scientific Reports, 9
  • [22] Characterization of Infections with Vancomycin-Intermediate Staphylococcus aureus (VISA) and Staphylococcus aureus with Reduced Vancomycin Susceptibility in South Korea
    Park, Jung Wan
    Lee, Hyungmin
    Kim, Jung Wook
    Kim, Bongyoung
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [23] Detection of Heteroresistant Vancomycin-Intermediate Staphylococcus aureus among Methicillin-Resistant Staphylococcus aureus
    Chaudhary, Bajarangi Lal
    Bisht, Dakshina
    Faujdar, Sameer
    ASIAN JOURNAL OF PHARMACEUTICAL RESEARCH AND HEALTH CARE, 2022, 14 (01) : 16 - 20
  • [24] First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital
    Ploy, MC
    Grélaud, C
    Martin, C
    de Lumley, L
    Denis, F
    LANCET, 1998, 351 (9110): : 1212 - 1212
  • [25] Contribution of vraSR and graSR Point Mutations to Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus
    Cui, Longzhu
    Neoh, Hui-min
    Shoji, Mitsutaka
    Hiramatsu, Keiichi
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (03) : 1231 - 1234
  • [26] Genome Sequence-Based Discriminator for Vancomycin-Intermediate Staphylococcus aureus
    Rishishwar, Lavanya
    Petit, Robert A., III
    Kraft, Colleen S.
    Jordan, I. King
    JOURNAL OF BACTERIOLOGY, 2014, 196 (05) : 940 - 948
  • [27] Vancomycin-intermediate Staphylococcus aureus in a home health-care patient
    Hageman, JC
    Pegues, DA
    Jepson, C
    Bell, RL
    Guinan, M
    Ward, KW
    Cohen, MD
    Hindler, JA
    Tenover, FC
    McAllister, SK
    Kellum, ME
    Fridkin, SK
    EMERGING INFECTIOUS DISEASES, 2001, 7 (06) : 1023 - 1025
  • [28] Comparative proteomic analysis of vancomycin-sensitive and vancomycin-intermediate resistant Staphylococcus aureus
    Hu, Jian
    Han, Xinjun
    Ma, Xiaoxue
    Chen, Xutao
    Zhou, Zhenping
    Peng, Peilan
    Yu, Zhao
    Hou, Yongzhi
    Han, Peiru
    Pang, Long
    Yang, Yali
    Xu, Jia
    Wu, Wenhui
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2024, 43 (01) : 203 - 208
  • [29] Risk factors for vancomycin treatment failure in heterogeneous vancomycin-intermediate Staphylococcus aureus bacteremia
    Yun, Ji Hyun
    Chang, Euijin
    Bae, Seongman
    Jung, Jiwon
    Kim, Min Jae
    Chong, Yong Pil
    Kim, Sung-Han
    Choi, Sang-Ho
    Lee, Sang-Oh
    Kim, Yang Soo
    MICROBIOLOGY SPECTRUM, 2024, 12 (08):
  • [30] Heterogeneous Vancomycin-Intermediate Staphylococcus aureus(HVISA) at a Tertiary Hospital in Malaysia
    Hamasalih, Bakhtiyar Mahmood
    Neoh, Hui-Min
    Ibrahim, Rosni
    Nor, Lailatul Akmar Mat
    Jamaluddin, Tengku Zetty Maztura Tengku
    SAINS MALAYSIANA, 2022, 51 (03): : 795 - 801